Major Depressive Disorder (MDD) also called mood disorder leads to a persistent feeling of sadness and often interferes with the daily life activity of the affected person. As per the DelveInsihgt, Major Depressive Disorder Prevalence was approximated to be 43,845,330 in the 7MM in 2020, which is on a gradual rise. Globally, some of the key companies are exploring novel therapies for the treatment of MDD which include Axsome Therapeutics, Luye Pharma, Sage Therapeutics, Relmada Therapeutics, Praxis Precision Medicines, Chase Therapeutics, Fabre-Kramer Pharmaceuticals, Intra-Cellular Therapies, Allergan, Gedeon Richter, and others.
The Major Depressive Disorder Market is expected to grow at a CAGR of 8.91% for the study period 2018–2030. The extensive research and development activity, increasing prevalence, heightened awareness around the condition, willingness to accept the condition as a medical illness, and growing demand for the treatment will be the key driving factors behind the MDD Market Growth. Similarly, several therapies for the treatment are under-development that is anticipated to launch in the coming years and are expected to provide relief to the affected people.
For more information, visit:
Major Depressive Disorder Clinical Trials and Prevalence